Jove
Visualize
Contact Us

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of diagnostic pitfalls in 125 genetically confirmed cases of distal myopathies.

Journal of neuromuscular diseases·2026
Same author

Exploring the clinical and genetic spectrum of Steel syndrome: two case reports and review of the literature.

Frontiers in medicine·2026
Same author

Different Diagnoses, Common Ancestry: 22q11.2 Deletion Syndrome and Wiskott-Aldrich Syndrome in the Same Family.

Molecular syndromology·2026
Same author

First 2-year experience of nationwide newborn screening for severe forms of T and B cell immunodeficiency: 2.3 million newborns analyzed using TREC and KREC in Russia.

Frontiers in immunology·2026
Same author

Duchenne Muscular Dystrophy in the Republic of North Ossetia-Alania: Epidemiological Study, Diagnostic Issues, and Treatment Prospects.

Genes·2025
Same author

Genetic Features of Albinism: A Comprehensive Analysis in the Russian Population.

Pigment cell & melanoma research·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Contradictory Effects on Hepatocytes in ASMD.

Maksim Sysoev1, Dmitri Solovyov1, Aleksandr Shestopalov1,2

  • 1Research Centre for Medical Genetics, 1 Moskvorechye St., 115522 Moscow, Russia.

International Journal of Molecular Sciences
|June 12, 2026
PubMed
Summary
This summary is machine-generated.

Acid sphingomyelinase deficiency (ASMD) causes sphingomyelin buildup in liver cells, leading to dysfunction. This review explores ASMD

Keywords:
acid sphingomyelinaseacid sphingomyelinase deficiencyautophagyhepatocytesliver dysfunctionlysosomal storage diseaselysosomessphingomyelin

Related Experiment Videos

Last Updated: Jun 13, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Area of Science:

  • Biochemistry
  • Cell Biology
  • Genetics

Background:

  • Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disorder.
  • It causes systemic sphingomyelin accumulation, frequently impacting the liver (91.4% of patients).
  • Hepatocytes show excessive sphingomyelin buildup, contributing to hepatic dysfunction.

Purpose of the Study:

  • To review the role of ASMD in hepatocytes.
  • To understand ASMD's disease mechanisms within the liver.
  • To explore potential therapeutic strategies for ASMD-related liver conditions.

Main Methods:

  • Literature review of clinical observations and experimental models.
  • Analysis of studies on ASMD models (murine and cellular).
  • Examination of patient data regarding autophagy and lipid metabolism.

Main Results:

  • Conflicting results exist regarding ASMD's effects on hepatocytes.
  • Murine models suggest ASMD may offer hepatoprotection via endoplasmic reticulum stress modulation.
  • ASMD patients display impaired autophagy and disrupted hepatic lipid homeostasis.

Conclusions:

  • ASMD significantly impacts hepatic lipid homeostasis and cellular processes.
  • Understanding ASMD's role in hepatocytes is crucial for developing targeted therapies.
  • Further research is needed to reconcile conflicting findings and optimize treatment approaches.